ReviewInternational journal of molecular sciences2025
DNMT Enzymes and Their Impact on Cervical Cancer: A State-of-the-Art Review.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PAX1/JAM3 methylation-a novel biomarker for early detection and accurate management of cervical adenocarcinoma.American journal of cancer research · 2026Review
- Cancer and Environmental Xenobiotics: Mechanisms, Controversies, and Innovations.Journal of xenobiotics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomic DNA methylation is an epigenetic modification that primarily occurs at CpG sites and is associated with the transcriptional repression of genes. This process plays a crucial role in maintaining cellular homeostasis and is catalyzed by a family of enzymes known as DNA methyltransferases (DNMTs), which includes DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L. DNMT1 is classified as a maintenance methyltransferase, whereas DNMT3A and DNMT3B are responsible for de novo methylation. Altered expression of DNMTs has been reported in various human diseases, including cancer. Cancer remains a major global health issue, with an estimated 20 million new cases and 9.7 million deaths reported in 2022. Among women, cervical cancer (CC) ranks fourth in both incidence and mortality worldwide, with persistent infection by high-risk human papillomavirus (HR-HPV) being the primary risk factor. Several studies have demonstrated that DNMT expression and activity are upregulated in CC, suggesting their potential as diagnostic and prognostic biomarkers. HR-HPV infection appears to increase DNMT expression, thereby promoting cervical carcinogenesis through aberrant methylation and subsequent silencing of tumor-suppressor genes such as PTEN, PAX1, and TSLC1. Furthermore, DNMTs are being explored as therapeutic targets in CC. In this review, we summarize the current state of the art regarding DNMTs in cervical cancer and discuss their functional roles and potential utility as diagnostic, prognostic, and therapeutic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.